Trial reportMedical science monitor : international medical journal of experimental and clinical research2025
Effect of Prophylactic Intraoperative Tranexamic Acid on Postpartum Blood Loss Following Cesarean Section at a Single Center.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The efficacy of local tranexamic acid injection in reducing intraoperative bleeding and improving surgical field quality in septoplasty: a randomized controlled trial.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Postpartum blood loss after cesarean section can be challenging to control, resulting in maternal morbidity and mortality. Tranexamic acid (TXA) is a synthetic reversible plasminogen inhibitor that is approved for the management of heavy menstrual bleeding, but off-label use has been described, including for the control of postpartum hemorrhage (PPH). This study aimed to compare postpartum blood loss after cesarean section in women treated with either tranexamic acid or placebo. MATERIAL AND METHODS This single-center clinical study conducted in Indonesia enrolled 88 women undergoing cesarean section. Participants were randomized into 2 groups: the treatment group (n=44) received 1 g of TXA intravenously at the time of surgical incision, and the placebo group (n=44) received 10 ml of saline. Blood loss was measured using a calibrated surgical suction device and pictogram, with total blood loss calculated by subtracting amniotic and irrigation fluids. RESULTS PPH occurred in 10.2% of all patients. Group A had significantly less blood loss than group B (mean=459.4 ml vs 686.3 ml; P<0.001). TXA was significantly protective, reducing the risk of PPH by 87.5% compared to group B (RR=0.125 [95% CI 0.016-0.958]; P=0.045). There were no significant differences in adverse effects between the 2 groups (P=0.101). CONCLUSIONS Intraoperative TXA administration significantly reduces blood loss and the risk of PPH in women undergoing cesarean sections. These findings support the routine use of TXA in cesarean management protocols to improve maternal safety and outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.